Andere Sprachen AngioDynamics, Inc.

Aktien

A0B9A5

US03475V1017

ANGO

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:10:06 16.05.2024			% 5 Tage	% 1. Jan.
6,365 ^USD	+0,08 %		+4,33 %	-18,56 %

06.05.	AngioDynamics, Inc. gibt Ergebnisse der Studie zur Extraktion akuter Lungenembolien mit dem Alphavac System (APEX-AV) bekannt	CI
05.04.	ANGIODYNAMICS, INC. : Von Oppenheimer zum Kauf angehoben	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions	06.05.
AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)	06.05.
North American Morning Briefing : Inflation Data, -2-	08.04.
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results, Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture	05.04.
AngioDynamics Receives 510(k) Clearance for AlphaVac F18 System in Treatment of PE	05.04.
AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device	04.04.
AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System	04.04.
AngioDynamics Gets FDA Clearance For Pulmonary Embolism Treatment	04.04.
AngioDynamics: Fiscal Q3 Earnings Snapshot	04.04.
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q3 Revenue $66M	04.04.
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture	04.04.
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	04.04.
AngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024	04.04.
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024	04.04.
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE	04.04.
AngioDynamics, Inc. Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE	04.04.
North American Morning Briefing : Focus Turns to -2-	04.04.
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate	02.04.
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.	01.04.
AngioDynamics Settles Multi-Year Patent Dispute with Becton Dickinson & Co	01.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen AngioDynamics, Inc.

Aktien

A0B9A5

US03475V1017

ANGO

Andere Sprachen

Filter